This application for renewal of the University of Virginia Cancer Center Support Grant builds on its original strengths in basic science research. However, it has been substantially re-structured to enhance the cohesiveness and cancer focus of the individual Programs and to facilitate meaningful interactions between laboratory and clinical scientists. The Cancer Center Support Grant has been organized into five Programs: Program 1, Cell Signaling focuses on molecular mechanisms of intracellular regulation including oncogenes, receptors, intracellular signal transduction, gene regulation and DNA replication, which are key to understanding normal and malignant growth. Program 2, Endocrinology focuses on growth, differentiation and regulation of endocrine cells, particularly of the pituitary, thyroid and gonads. This Program has a distinguished record of clinical, translational and fundamental research. Program 3, Immunology has great strengths in the areas of immune cell activation, antigen presentation/recognition and auto-immunity, issues which are of fundamental and practical importance in cancer immunology. Program 4, Metastasis, Invasion and Cell Surfaces is a new Program, built on existing basic science strengths in membranes, extracellular matrices and proteases, which will be brought to bear on the important problems of tumor invasion and metastasis. Program 5, Clinical Oncology is a new Program designed to provide the clinical venue for interactions with the four laboratory-based Programs. Its goal is to identify cellular or immunologic targets for therapy or diagnosis; develop drugs or biologicals to attack that target; and test these drugs or biologicals in the clinical setting. Inter-disciplinary working groups with individuals drawn from each stage of the development process are being established to facilitate this process. In addition to the Programmatic re-structuring, the Cancer Center has consolidated its inpatient and ambulatory cancer care facilities, established a centralized clinical trials protocol review and monitoring system, coordinated oncology research programs with existing areas of related research strength and initiated the recruitment of clinical and translational oncology researchers. The net result of these changes is expected to be a system which enhances understanding of cancer and facilitates scientific improvements in cancer treatment, diagnosis and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-12
Application #
6172291
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1987-07-01
Project End
2004-07-31
Budget Start
2000-08-01
Budget End
2001-07-31
Support Year
12
Fiscal Year
2000
Total Cost
$1,959,831
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications